Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Acta Biochim Biophys Sin (Shanghai). 2012 Aug;44(8):678-84. doi: 10.1093/abbs/gms051. Epub 2012 Jun 17.
Radiotherapy is the major treatment for nasopharyngeal carcinoma, a malignant tumor of epithelial origin. In this process, a tracer with high sensitivity is pivotal for diagnostic imaging in radiotherapy. Here, we designed a novel multifunctional magnetic silver nanocomposite, Fe(3)O(4)/Ag conjugated to an epidermal growth factor receptor-specific antibody (C225), which can be potentially used for synchronous cancer therapy and diagnosis via magnetic resonance imaging. Characteristics of Fe(3)O(4)/Ag/C225 were determined by transmission electron microscopy, energy dispersive X-ray spectroscopy, ultraviolet spectra, and dynamic light scattering. The results demonstrated that Fe(3)O(4)/Ag/C225 nanoparticles were spherical and dispersed well in water. The activity of C225 was preserved ∼80% in the Fe(3)O(4)/Ag/C225 nanoparticles. Futhermore, we tested the cytotoxicity and radiosensitivity of the nanocomposite for human nasopharyngeal carcinoma cell lines (CNEs) in vitro. MTT analysis revealed that Fe(3)O(4)/Ag/C225 could inhibit the proliferation of CNEs in a dose- and time-dependent manner. The clonogenic assay indicated that Fe(3)O(4)/Ag/C225 combined with X-ray treatment could increase the sensitivity of CNEs to irradiation. In a summary, the novel multifunctional nanocomposite Fe(3)O(4)/Ag/C225 might be a potential radiosensitizer for treating malign tumors in the clinic.
放射疗法是治疗鼻咽癌的主要方法,鼻咽癌是一种上皮来源的恶性肿瘤。在这个过程中,高灵敏度的示踪剂对于放射治疗的诊断成像至关重要。在这里,我们设计了一种新型多功能磁性银纳米复合材料,Fe(3)O(4)/Ag 与表皮生长因子受体特异性抗体(C225)偶联,可通过磁共振成像用于同步癌症治疗和诊断。通过透射电子显微镜、能谱、紫外光谱和动态光散射来确定 Fe(3)O(4)/Ag/C225 的特性。结果表明,Fe(3)O(4)/Ag/C225 纳米颗粒呈球形且在水中分散良好。在 Fe(3)O(4)/Ag/C225 纳米颗粒中,C225 的活性保持在约 80%。此外,我们在体外测试了该纳米复合材料对人鼻咽癌细胞系(CNEs)的细胞毒性和放射敏感性。MTT 分析表明,Fe(3)O(4)/Ag/C225 可以以剂量和时间依赖的方式抑制 CNEs 的增殖。集落形成实验表明,Fe(3)O(4)/Ag/C225 与 X 射线联合治疗可以增加 CNEs 对辐射的敏感性。总之,新型多功能纳米复合材料 Fe(3)O(4)/Ag/C225 可能是一种有潜力的临床治疗恶性肿瘤的放射增敏剂。